Sinco Pharmaceutical Holdings (HKSE:06833) Total Liabilities : HK$1,381 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Total Liabilities?

Sinco Pharmaceutical Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was HK$1,381 Mil.

Sinco Pharmaceutical Holdings's quarterly Total Liabilities increased from Dec. 2022 (HK$916.29 Mil) to Jun. 2023 (HK$1,133.77 Mil) and increased from Jun. 2023 (HK$1,133.77 Mil) to Dec. 2023 (HK$1,381.03 Mil).

Sinco Pharmaceutical Holdings's annual Total Liabilities declined from Dec. 2021 (HK$1,050.45 Mil) to Dec. 2022 (HK$916.29 Mil) but then increased from Dec. 2022 (HK$916.29 Mil) to Dec. 2023 (HK$1,381.03 Mil).

Sinco Pharmaceutical Holdings Total Liabilities Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Total Liabilities Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

874.68

1,289.31

1,050.45

916.29

1,381.03

Sinco Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial														1,050.45	1,180.50	916.29	1,133.77	1,381.03

Sinco Pharmaceutical Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sinco Pharmaceutical Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1347.576	+	(7.34	+	26.118
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,381

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2067.984	-	686.95
	=	1,381

Sinco Pharmaceutical Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1347.576	+	(7.34	+	26.118
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,381

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	2067.984	-	686.95
	=	1,381

Sinco Pharmaceutical Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Executives

Huang Zhijian	2305 Beneficiary of a trust
Fullwealth Holdings Limited	2201 Interest of corporation controlled by you
Risun Investments Limited	2101 Beneficial owner
Wickhams Cay Trust Company Limited	2301 Trustee
Huang Xiangbin	2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines